182 related articles for article (PubMed ID: 27196758)
1. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
3. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
4. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
5. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
6. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
7. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
9. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implication of HER2 in advanced biliary tract cancer.
Nam AR; Kim JW; Cha Y; Ha H; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Oncotarget; 2016 Sep; 7(36):58007-58021. PubMed ID: 27517322
[TBL] [Abstract][Full Text] [Related]
12. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
Yu L; Guo W; Liu L; Zhang G; Zhang F; Qu Y; Liu Y; Li H; Li H
Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
16. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
19. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
20. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]